Protein / target

Fatty acid-binding protein, brain

Encoded byFABP7O15540Homo sapiensSwiss-Prot

UniProt: O15540 Ensembl: ENSG00000164434 HGNC: HGNC:3562 NCBI Gene: 2173

Small-molecule tractable

Druggability

Structure with Ligand

Research papers

Protein at a glance

Biological role

Lipid transporter

Strongest disease association

Idiopathic Pulmonary Fibrosis

Via encoding gene FABP7 · Genetic evidence · score 0.41

Research activity

Emerging research

3 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

B-FABP could be involved in the transport of a so far unknown hydrophobic ligand with potential morphogenic activity during CNS development.

View complete UniProt function annotation

B-FABP could be involved in the transport of a so far unknown hydrophobic ligand with potential morphogenic activity during CNS development. It is required for the establishment of the radial glial fiber system in developing brain, a system that is necessary for the migration of immature neurons to establish cortical layers (By similarity)

Subcellular location

Cytoplasm

Domains and Gene Ontology detail (10)

Gene Ontology

Ccytosol
Cnucleus
Ffatty acid binding
Flipid binding
Flipid transporter activity
Pepithelial cell proliferation
Pfatty acid transport
Pnegative regulation of cell population proliferation
Pnervous system development
Ptriglyceride catabolic process

132 aa · 15 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Lipid & lipoprotein metabolismGOCell proliferation & survivalGO

View supporting evidence

Lipid & lipoprotein metabolism

·fatty acid binding
·lipid transporter activity
·fatty acid transport
·triglyceride catabolic process

Cell proliferation & survival

·negative regulation of cell population proliferation

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene FABP7

Gene-level evidence surfaced through the gene FABP7 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Idiopathic Pulmonary Fibrosis

0.41Limited support

Genetic evidence dominant · Open Targets 0.25

Alcohol drinking

0.25Preliminary

Genetic evidence dominant · Open Targets 0.15

Urolithiasis

0.22Preliminary

Genetic evidence dominant · Open Targets 0.13

Temporomandibular Joint Disorders

0.21Preliminary

Genetic evidence dominant · Open Targets 0.13

Glioblastoma

0.14Preliminary

Literature evidence dominant · Open Targets 0.11 · no direct causal or clinical evidence

View evidence synthesis (5)

Idiopathic Pulmonary FibrosisLimited support

0.41

agreement 0.29–0.53

Genetic100%

Open Targets aggregate 0.25 · 1 independent evidence family

Alcohol drinkingPreliminary

0.25

agreement 0.13–0.37

Genetic100%

Open Targets aggregate 0.15 · 1 independent evidence family

UrolithiasisPreliminary

0.22

agreement 0.10–0.34

Genetic100%

Open Targets aggregate 0.13 · 1 independent evidence family

Temporomandibular Joint DisordersPreliminary

0.21

agreement 0.09–0.33

Genetic100%

Open Targets aggregate 0.13 · 1 independent evidence family

GlioblastomaPreliminary

0.14

agreement 0.00–0.41

Literature100%

Open Targets aggregate 0.11 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Idiopathic Pulmonary Fibrosis0.25

Alcohol drinking0.15

Urolithiasis0.13

Temporomandibular Joint Disorders0.13

Glioblastoma0.11

Neoplasms0.11

Glioma0.10

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging